1
Country: Italy | Funding: $206.3M
AAVantgarde Bio is a clinical-stage biotechnology company that develops retinal disease gene therapies. One of its drugs is intended at patients with Stargardt disease, a leading cause of vision loss in children and young adults. By delivering the full-length ABCA4 protein, AAVantgarde hopes that it can address the root cause of this eye condition. Another asset is for patients with retinitis pigmentosa associated with Usher syndrome - rare genetic disease that affects both hearing and vision. AAVantgarde says that its proprietary technology has demonstrated high transduction, protein expression and safety for both Stargardt and Usher 1B.
AAVantgarde Bio is a clinical-stage biotechnology company that develops retinal disease gene therapies. One of its drugs is intended at patients with Stargardt disease, a leading cause of vision loss in children and young adults. By delivering the full-length ABCA4 protein, AAVantgarde hopes that it can address the root cause of this eye condition. Another asset is for patients with retinitis pigmentosa associated with Usher syndrome - rare genetic disease that affects both hearing and vision. AAVantgarde says that its proprietary technology has demonstrated high transduction, protein expression and safety for both Stargardt and Usher 1B.
2
Country: USA | Funding: $763.8M
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform to treat rare diseases where no, or only palliative, therapies exist.
3
Country: USA | Funding: $694.9M
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
4
Country: USA | Funding: $513M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients (including with Thyroid Eye Disease ).
5
Country: USA | Funding: $317.8M
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
6
Country: UK | Funding: $290.1M
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
7
Country: France | Funding: $274.4M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
8
Country: USA | Funding: $237.6M
Atsena Therapeutics develops blindness gene therapy
Atsena Therapeutics develops blindness gene therapy
9
Country: Israel | Funding: $190M
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
ForSight Robotics created surgical platform designed specifically for ophthalmological (eye) surgeries — a category requiring a great deal of precision.
10
Country: USA | Funding: $173.4M
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx is developing additional AI-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk.
11
Country: USA | Funding: $162.7M
Meira Gene Therapy is argeting inherited retinal diseases with therapies designed to halt vision loss.
Meira Gene Therapy is argeting inherited retinal diseases with therapies designed to halt vision loss.
12
Country: Israel | Funding: $130M
OrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties. OrCam has created a technologically advanced device unique in its ability to provide visual aid through a discreet wearable platform and simple easy-to-use interface which serves to enhance the daily lives of people with vision loss.
OrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties. OrCam has created a technologically advanced device unique in its ability to provide visual aid through a discreet wearable platform and simple easy-to-use interface which serves to enhance the daily lives of people with vision loss.
13
Country: France | Funding: $127.6M
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
14
Country: Israel | Funding: $126M
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
15
Country: USA | Funding: $120M
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
16
Country: USA | Funding: $120M
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
17
Country: France | Funding: €111.1M
Coave Therapeutics develops retinal gene therapy
Coave Therapeutics develops retinal gene therapy
18
Country: USA | Funding: $104.8M
Claris works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision making
Claris works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision making
19
Country: USA | Funding: $100M
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
Ollin is dedicated to advancing novel therapeutic candidates that target a broader spectrum of biology to improve outcomes for patients with severe, vision-threatening conditions.
20
Country: China | Funding: $78.5M
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
21
Country: USA | Funding: $57M
EyeQue is a maker of at home visual acuity tests. Dedicated to inspiring people to learn about & care for their eyes by putting affordable, accurate vision tests directly into their hands.
EyeQue is a maker of at home visual acuity tests. Dedicated to inspiring people to learn about & care for their eyes by putting affordable, accurate vision tests directly into their hands.
22
Country: USA | Funding: $56M
Visus Therapeutics is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.
Visus Therapeutics is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.
23
Country: USA | Funding: $55.3M
XP Health is an artificial intelligence-powered vision benefits platform for employees.
XP Health is an artificial intelligence-powered vision benefits platform for employees.
24
Country: USA | Funding: $46.8M
Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases.
Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases.
25
Country: USA | Funding: $47.4M
Eyenuk, Inc. is a global digital health company and leader in real-world AI eye screening for autonomous disease detection
Eyenuk, Inc. is a global digital health company and leader in real-world AI eye screening for autonomous disease detection
26
Country: USA | Funding: $43.1M
Opternative builds online eye exam, the most convenient way to get a prescription from an ophthalmologist for contacts and glasses. The exam can be taken from anywhere, at any time, and a doctor issued prescription can be used to shop everywhere. Eye exams for glasses and contact prescriptions are just the beginning. We envision a world where technology allows patients and doctors to connect to make all aspects of vision care more convenient, accessible and even fun!
Opternative builds online eye exam, the most convenient way to get a prescription from an ophthalmologist for contacts and glasses. The exam can be taken from anywhere, at any time, and a doctor issued prescription can be used to shop everywhere. Eye exams for glasses and contact prescriptions are just the beginning. We envision a world where technology allows patients and doctors to connect to make all aspects of vision care more convenient, accessible and even fun!
27
Country: USA | Funding: $42.4M
Abpro Therapeutics develops antibody drugs for cancer and vascular eye disease
Abpro Therapeutics develops antibody drugs for cancer and vascular eye disease
28
Country: Finland | Funding: $40.9M
IXI is redefining vision correction with the world’s first adaptive eyewear, providing seamless clarity wherever you look.
IXI is redefining vision correction with the world’s first adaptive eyewear, providing seamless clarity wherever you look.
29
Country: Israel | Funding: $38.1M
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.
30
Country: USA | Funding: $32.5M
Lumata Health is a practice management platform for ophthalmology
Lumata Health is a practice management platform for ophthalmology
31
Country: Switzerland | Funding: $33.4M
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
32
Country: USA | Funding: $26M
Simple Contacts allows you to take a vision test and reorder your contacts In just five minutes, without the office visit.
Simple Contacts allows you to take a vision test and reorder your contacts In just five minutes, without the office visit.
33
Country: South Korea | Funding: $24.8M
Medi Whale offers medical AI software for eye disease detection. Its devices assess cardiovascular risk through the use of retinal imagery and artificial intelligence
Medi Whale offers medical AI software for eye disease detection. Its devices assess cardiovascular risk through the use of retinal imagery and artificial intelligence
34
Country: Canada | Funding: $20.7M
eSight is the only patented, assistive-device of its kind anywhere in the world. eSight is wearable, handsfree, portable - and most importantly, eSight is a non-surgical device. eSight is currently registered with the United States FDA and Health Canada.
eSight is the only patented, assistive-device of its kind anywhere in the world. eSight is wearable, handsfree, portable - and most importantly, eSight is a non-surgical device. eSight is currently registered with the United States FDA and Health Canada.
35
Country: Australia | Funding: $18M
Bionic Vision Technologies develops visual prostheses to restore vision to the blind. The devices operate by electrically stimulating the remaining retinal cells in patients with retinal degeneration.
Bionic Vision Technologies develops visual prostheses to restore vision to the blind. The devices operate by electrically stimulating the remaining retinal cells in patients with retinal degeneration.
36
Country: USA | Funding: $17M
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
37
Country: Israel | Funding: $16M
NovaSight brings pediatric vision care into the digital age. Its revolutionary eye tracking-based solutions aim to prevent pediatric vision loss through rapid vision assessment and innovative vision therapy.
NovaSight brings pediatric vision care into the digital age. Its revolutionary eye tracking-based solutions aim to prevent pediatric vision loss through rapid vision assessment and innovative vision therapy.
38
Country: Germany | Funding: €13.2M
Dopavision is a therapeutic company developing a digital therapeutic for myopia.
Dopavision is a therapeutic company developing a digital therapeutic for myopia.
39
Country: USA | Funding: $10M
AEYE Health is a digital health company focused on automated, AI-based diagnostic screening solutions for retinal imaging. The company’s system is designed to enable clinicians to detect a variety of medical conditions, prevent blindness, and save lives.
AEYE Health is a digital health company focused on automated, AI-based diagnostic screening solutions for retinal imaging. The company’s system is designed to enable clinicians to detect a variety of medical conditions, prevent blindness, and save lives.
40
Country: Germany | Funding: $8.5M
Our EYEMATE eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing. It also consists of an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage. A GSM module can be connected with the hand held device for transfer of measurement data to an internet-based database.
Our EYEMATE eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing. It also consists of an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage. A GSM module can be connected with the hand held device for transfer of measurement data to an internet-based database.
41
Country: USA | Funding: $8.1 m
We developed the world’s first smartphone based wavefront autorefractor, SVOne, to combat this global challenge. To date, the SVOne is used in over 300 eye clinics across the United States and in 23 countries. Today, the team continues to create industry-changing technology to reinvent the future of vision care.
We developed the world’s first smartphone based wavefront autorefractor, SVOne, to combat this global challenge. To date, the SVOne is used in over 300 eye clinics across the United States and in 23 countries. Today, the team continues to create industry-changing technology to reinvent the future of vision care.
42
Country: Israel | Funding: $7.2M
IOPtima develops minimally-invasive surgical ophthalmic devices. The company’s flagship product IOPtimate is a surgical system for the treatment of Glaucoma, which utilizes a CO2 laser technology to significantly reduce internal eye pressure (“IOP”), by restoring the natural fluid percolation without penetrating into the eye.
IOPtima develops minimally-invasive surgical ophthalmic devices. The company’s flagship product IOPtimate is a surgical system for the treatment of Glaucoma, which utilizes a CO2 laser technology to significantly reduce internal eye pressure (“IOP”), by restoring the natural fluid percolation without penetrating into the eye.
43
Country: India | Funding: $7.1M
We envision a world where all people feel empowered and able to make informed decisions about their health. We are, in particular, passionate about sight - we believe everyone has the right to experience their world and their journey with perfect visual performance. We are not satisfied with the current state of vision care, and we see a near future where mobile technologies and self-diagnostics will create a true sea change, bringing light and possibility to eyes everywhere. At EyeNetra, we are committed to making that future real.
We envision a world where all people feel empowered and able to make informed decisions about their health. We are, in particular, passionate about sight - we believe everyone has the right to experience their world and their journey with perfect visual performance. We are not satisfied with the current state of vision care, and we see a near future where mobile technologies and self-diagnostics will create a true sea change, bringing light and possibility to eyes everywhere. At EyeNetra, we are committed to making that future real.
44
Country: Lithuania | Funding: $6.6M
At Oxipit we are harnessing the latest AI and Machine Learning developments for better patient outcomes all over the world.
At Oxipit we are harnessing the latest AI and Machine Learning developments for better patient outcomes all over the world.
45
Country: USA | Funding: $3M
TeamedOn is advancing gene therapies for rare diseases and currently focused on ophthalmic indications. We are developing innovative medicine to treat inherited retinal disorders (IRDs) and other eye diseases with significant unmet medical need.
TeamedOn is advancing gene therapies for rare diseases and currently focused on ophthalmic indications. We are developing innovative medicine to treat inherited retinal disorders (IRDs) and other eye diseases with significant unmet medical need.
46
Country: Canada | Funding: CA$3.8M
For a half century, ophthalmic surgeons have envisioned an intraocular lens capable of restoring eyesight at all distances. Ocumetics Technology Corporation was founded to achieve this goal. Employing state-of-the art materials and production techniques, Ocumetics Technology Corporation is in the process of developing a highly advanced intraocular lens, one that is capable of restoring clear vision at all distances, without glasses or contact lenses, and without the visual quality problems that have plagued current accommodative and multifocal intraocular lens designs.
For a half century, ophthalmic surgeons have envisioned an intraocular lens capable of restoring eyesight at all distances. Ocumetics Technology Corporation was founded to achieve this goal. Employing state-of-the art materials and production techniques, Ocumetics Technology Corporation is in the process of developing a highly advanced intraocular lens, one that is capable of restoring clear vision at all distances, without glasses or contact lenses, and without the visual quality problems that have plagued current accommodative and multifocal intraocular lens designs.
48
Country: Ukraine | Funding: $1M
Altris.AI, a health tech company, develops ophthalmology deep learning platform for retinal diseases detection from Optical Coherence Tomography (OCT) scans or Fundus images at early, asymptomatic stages by learning from a large dataset of clinical cases.
Altris.AI, a health tech company, develops ophthalmology deep learning platform for retinal diseases detection from Optical Coherence Tomography (OCT) scans or Fundus images at early, asymptomatic stages by learning from a large dataset of clinical cases.
49
Country: Ukraine | Funding: $1M
AI-powered ophthalmic image management system that helps to detect 54 pathologies and 49 pathological signs on OCT scans.
AI-powered ophthalmic image management system that helps to detect 54 pathologies and 49 pathological signs on OCT scans.
50
Country: Singapore
Cornea Biosciences was founded in 2011 with the express objective of furthering development of the bioengineered cornea, and providing this cornea to the millions of people unilaterally or bilaterally blind from corneal disease or injury and unable to obtain a corneal transplant due to a severe shortage of human donor corneas. The company’s cornea is the result of ten years of research and development conducted at the University of Ottawa in Canada and Linkoping University in Sweden.
Cornea Biosciences was founded in 2011 with the express objective of furthering development of the bioengineered cornea, and providing this cornea to the millions of people unilaterally or bilaterally blind from corneal disease or injury and unable to obtain a corneal transplant due to a severe shortage of human donor corneas. The company’s cornea is the result of ten years of research and development conducted at the University of Ottawa in Canada and Linkoping University in Sweden.
